3 news items
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
IMCR
31 May 24
, and demonstrated durable clinical benefit. "Brenetafusp continues to demonstrate promising monotherapy clinical activity
Immunocore to present at the Jefferies Global Healthcare Conference
IMCR
30 May 24
and therapeutic potential of KIMMTRAK for mUM; the expected clinical benefits of KIMMTRAK and the Company's other product candidates, including extended
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
IMCR
29 May 24
Affairs, Immunocore said: "The decision to launch a registrational trial in cutaneous melanoma was based on KIMMTRAK's overall survival benefit
- Prev
- 1
- Next